{
    "clinical_study": {
        "@rank": "6517", 
        "arm_group": {
            "arm_group_label": "nanoparticle albumin-bound paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin in stage \u2161 B and IIIA squamous cell carcinoma of the lung"
        }, 
        "brief_summary": {
            "textblock": "Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung\n      squamous cell carcinoma has a better tumor response rate and safety, therefore.The main\n      purpose of this study is to observe the safety and efficacy of albumin-bound paclitaxel /\n      carboplatin in the treatment of lung squamous cell carcinoma of stage IIB and IIIA."
        }, 
        "brief_title": "Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage \u2161 B and IIIA Squamous Cell Carcinoma of the Lung", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Carcinoma, Squamous Cell", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Albumin-bound paclitaxel plus carboplatin regimen in advanced NSCLC especially in lung\n      squamous cell carcinoma has a better tumor response rate and safety, therefore, this program\n      is applied to neoadjuvant therapy, may obtain better tumor pathological remission rate,\n      improve the operation resection rate, thus improve the prognosis.The main purpose of this\n      study is to observe the safety and efficacy of albumin-bound paclitaxel / carboplatin in the\n      treatment of lung squamous cell carcinoma of stage IIB and IIIA."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.Histological or cytological diagnosis of lung squamous cell carcinoma of stage IIB and\n        IIIA.\n\n        2.18 years or older 3.ECOG Performance Status no more than 2; 4.Appraisable disease, the\n        presence of at least three lesions if longest diameter <10 mm by brain MRI; 5.Haemoglobin\n        10.0 g/dl, Absolute neutrophil count (ANC) 1.5 x 10E9/L, platelets 100 x 10E9/L; 6.Total\n        bilirubin 1.5 x upper limit of normal (ULN); 7.ALT and AST < 2.5 x ULN in the absence of\n        liver metastases, or < 5 x ULN in case of liver metastases; 8.Creatinine clearance\n        60ml/min (calculated according to Cockcroft-gault formula).\n\n        Exclusion Criteria:\n\n          1. Any systemic anticancer treatment for NSCLC\n\n          2. Local radiotherapy for NSCLC.\n\n          3. In this study within five years prior to the start of treatment with other than NSCLC\n             patients with other cancers.\n\n          4. Any instability in systemic disease, including: active infection, absence of control\n             hypertension, unstable angina, begins in the last 3 months of angina pectoris,\n             congestive heart failure\n\n          5. HIV infection;\n\n          6. Allergic to paclitaxel or Platinum;\n\n          7. mixed with adenocarcinoma, small cell lung cancer;\n\n          8. Pregnant or lactating women;\n\n          9. Other researchers believe that does not fit into the group"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01872403", 
            "org_study_id": "FAH20120906", 
            "secondary_id": "FAHGuangzhou011"
        }, 
        "intervention": {
            "arm_group_label": "nanoparticle albumin-bound paclitaxel", 
            "description": "Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage \u2161 B and IIIA squamous cell carcinoma of the lung:", 
            "intervention_name": "nanoparticle albumin-bound paclitaxel/carboplatin", 
            "intervention_type": "Drug", 
            "other_name": "paclitaxel /carboplatin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Carboplatin", 
                "Paclitaxel"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Squamous Cell Carcinoma of the lung", 
        "lastchanged_date": "June 6, 2013", 
        "location": {
            "contact": {
                "email": "hejx@vip.163.com", 
                "last_name": "jianxing HE, MD", 
                "phone": "+86-20-83062808"
            }, 
            "contact_backup": {
                "email": "yxy701@126.com", 
                "last_name": "xinyun yang, master", 
                "phone": "+86-20-83062808"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510120"
                }, 
                "name": "The First Affiliated Hospital of Guangzhou Medical College"
            }, 
            "investigator": {
                "last_name": "jianxing he, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage \u2161 B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center", 
        "other_outcome": {
            "measure": "The rate of pathology down-stage of lymph nodes", 
            "safety_issue": "No", 
            "time_frame": "1 day (the date of surgery)"
        }, 
        "overall_contact": {
            "email": "hejx@vip.163.com", 
            "last_name": "jianxing he, MD", 
            "phone": "+86-02-83062808"
        }, 
        "overall_contact_backup": {
            "email": "yxy701@126.com", 
            "last_name": "xinyun yang, master", 
            "phone": "+86-02-83062808"
        }, 
        "overall_official": {
            "affiliation": "The First Affiliated Hospital of Guangzhou Medical University", 
            "last_name": "jianxing he, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Tumor ORR  and Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "From date of randomization until the date of progression, assessed up to 2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01872403"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The First Affiliated Hospital of Guangzhou Medical University", 
            "investigator_full_name": "Jianxing He", 
            "investigator_title": "The First Affiliated Hospital of Guangzhou Medical University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "PFS", 
            "safety_issue": "No", 
            "time_frame": "From date of surgery until the date of first documented progression, assessed up to 30 months"
        }, 
        "source": "The First Affiliated Hospital of Guangzhou Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The First Affiliated Hospital of Guangzhou Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}